1171 Single Fraction Stereotactic Radiosurgery for Basal Ganglia Metastases: An Institutional Experience of 113 Treated Lesions

View at publisher Summarise with VIRAT
Authors: Amirhossein Akhavan-Sigari, Ruchit P. Jain, Ahed H. Kattaa, Elaheh Shaghaghian, Yusuke S. Hori, Rodas Asrat Kassu, Fred C. Lam, Deya Abu-Reesh, Sara C Emrish, Louisa Ustrzynski, Armine T. Tayag, Lei Wang
+6 more Erqi Liu Pollum, Scott G. Soltys, David Jaehyun Park, Melanie Hayden Gephart, Gordon Li, Steven Daniel Chang
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

INTRODUCTION: Stereotactic radiosurgery (SRS) is a well-established treatment for various brain lesions and the current standard of care for brain metastases involving deep-seated lesions. METHODS: We retrospectively reviewed patients with BM involving the BG who underwent single fraction SRS at our institution from January 2006 to June 2024. Local tumor control (LTC) – based on Response Evaluation Criteria in Solid Tumors 1.1 – intracranial progression free survival (iPFS), overall survival (OS), and radiation-induced adverse events using the Common Terminology Criteria for Adverse Events (CTCAE) were evaluated. RESULTS: A total of 98 patients with 113 BG metastases underwent sfSRS. the median age was 58 years, and the most common primary malignancies were non-small-cell lung carcinoma (41.8%), followed by breast carcinoma (32.6%), and melanoma (13.2%). the median maximum lesion diameter was 5 mm (range: 2-41 mm). Lesions were treated with a median maximum dose of 29.06 Gy and prescribed dose of 22 Gy. At SRS, 58.1% of patients were asymptomatic or had symptoms from other lesions. The most common BG-related symptoms were sensory deficits (18.3%) and balance/coordination issues (14.3%). Severe toxicities were rare (≤0.9%). Median time to last follow-up was 9 months. The median OS was 11 months (95% CI: 8.8-13.2 months). The LTC rate at 6- and 12-month rates were 94.7% and 91.4%. The median time to distant intracranial progression was 8 (95% CI: 5.9-10.1) months. CONCLUSIONS: Single-fraction SRS represents a safe and effective treatment modality for BM localized to the BG, demonstrating high LTC rates. However, the limited OS and low iPFS of both systemic and intracranial disease compromise the ability to evaluate the long-term efficacy of sfSRS for the treatment of such lesions.

Fields of Study & Subjects

Brain Metastases and Treatment Management of metastatic bone disease Glioma Diagnosis and Treatment

Publication details

Journal / source
Neurosurgery
Volume
72
Issue
Supplement_1
Pages
227–227
Publication date
26 March 2026
Language
EN